These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 33742206)

  • 21. GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study.
    Melo M; Busso CE; Bellver J; Alama P; Garrido N; Meseguer M; Pellicer A; Remohí J
    Reprod Biomed Online; 2009 Oct; 19(4):486-92. PubMed ID: 19909588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology.
    Al-Inany HG; Youssef MA; Ayeleke RO; Brown J; Lam WS; Broekmans FJ
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD001750. PubMed ID: 27126581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of GnRH-agonist trigger for the final maturation of oocytes in normal and low responders undergoing planned oocyte cryopreservation.
    Maslow BL; Guarnaccia M; Stefanacci C; Ramirez L; Klein JU
    Hum Reprod; 2020 May; 35(5):1054-1060. PubMed ID: 32406915
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison between a GnRH antagonist and a GnRH agonist flare-up protocol in oocyte donors: a randomized clinical trial.
    Bodri D; Vernaeve V; Guillén JJ; Vidal R; Figueras F; Coll O
    Hum Reprod; 2006 Sep; 21(9):2246-51. PubMed ID: 16704995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.
    Vuong TN; Ho MT; Ha TD; Phung HT; Huynh GB; Humaidan P
    Fertil Steril; 2016 Feb; 105(2):356-63. PubMed ID: 26523330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progesterone-primed ovarian stimulation in oocyte donation: a model for elective fertility preservation?
    Devesa M; Racca A; Clúa E; Casato C; García S; Polyzos NP; Martínez F
    Reprod Biomed Online; 2022 Jun; 44(6):1015-1022. PubMed ID: 35339364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predicting suboptimal oocyte yield following GnRH agonist trigger by measuring serum LH at the start of ovarian stimulation.
    Popovic-Todorovic B; Santos-Ribeiro S; Drakopoulos P; De Vos M; Racca A; Mackens S; Thorrez Y; Verheyen G; Tournaye H; Quintero L; Blockeel C
    Hum Reprod; 2019 Oct; 34(10):2027-2035. PubMed ID: 31560740
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What is the optimal GnRH antagonist protocol for ovarian stimulation during ART treatment? A systematic review and network meta-analysis.
    Venetis CA; Storr A; Chua SJ; Mol BW; Longobardi S; Yin X; D'Hooghe T
    Hum Reprod Update; 2023 May; 29(3):307-326. PubMed ID: 36594696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Natural cycle in vitro fertilisation (IVF) for subfertile couples.
    Allersma T; Farquhar C; Cantineau AE
    Cochrane Database Syst Rev; 2013 Aug; 2013(8):CD010550. PubMed ID: 23990351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.
    Bodri D; Guillén JJ; Galindo A; Mataró D; Pujol A; Coll O
    Fertil Steril; 2009 Feb; 91(2):365-71. PubMed ID: 18367175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a "freeze-all" strategy: a prospective multicentric study.
    Griesinger G; Schultz L; Bauer T; Broessner A; Frambach T; Kissler S
    Fertil Steril; 2011 May; 95(6):2029-33, 2033.e1. PubMed ID: 21371705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles.
    Mochtar MH; Danhof NA; Ayeleke RO; Van der Veen F; van Wely M
    Cochrane Database Syst Rev; 2017 May; 5(5):CD005070. PubMed ID: 28537052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GnRH agonist versus HCG triggering in different IVF/ICSI cycles of same patients: a retrospective study.
    Yılmaz N; Ceran MU; Ugurlu EN; Gülerman HC; Engin Ustun Y
    J Obstet Gynaecol; 2020 Aug; 40(6):837-842. PubMed ID: 31791167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS.
    Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
    Hum Reprod; 2013 Jul; 28(7):1929-42. PubMed ID: 23624582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Depot versus daily administration of gonadotrophin-releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles.
    Albuquerque LE; Tso LO; Saconato H; Albuquerque MC; Macedo CR
    Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD002808. PubMed ID: 23440788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Higher probability of live-birth in high, but not normal, responders after first frozen-embryo transfer in a freeze-only cycle strategy compared to fresh-embryo transfer: a meta-analysis.
    Bosdou JK; Venetis CA; Tarlatzis BC; Grimbizis GF; Kolibianakis EM
    Hum Reprod; 2019 Mar; 34(3):491-505. PubMed ID: 30689865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparison of GnRH agonists and antagonists in an ovular donation program].
    Saucedo de la Llata E; Moraga Sánchez MR; Batiza Reséndiz V; Santos Haliscak R; Galache Vega P; Hernández Ayup S
    Ginecol Obstet Mex; 2004 Feb; 72():53-6. PubMed ID: 15216901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Triggering with GnRH agonist in oocyte-donation cycles: oestradiol monitoring is not necessary during ovarian stimulation.
    Castillo JC; Dolz M; Moreno J; Gijón L; Ferrer R; Ferrero E; Bonilla-Musoles F
    Reprod Biomed Online; 2012 Feb; 24(2):247-50. PubMed ID: 22196891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Definition of a clinical strategy to enhance the efficacy, efficiency and safety of egg donation cycles with imported vitrified oocytes.
    Rienzi L; Cimadomo D; Maggiulli R; Vaiarelli A; Dusi L; Buffo L; Amendola MG; Colamaria S; Giuliani M; Bruno G; Stoppa M; Ubaldi FM
    Hum Reprod; 2020 Apr; 35(4):785-795. PubMed ID: 32240287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.